Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
JAZZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$95.49 - $148.06
Previous CloseN/A
Volume75.28K
Average Volume (3M)1.42M
Market Cap
$6.24B
Enterprise Value$10.75B
Total Cash (Recent Filing)$19.00M
Total Debt (Recent Filing)$120.55M
Price to Earnings (P/E)11.8
Beta0.56
Next Earnings
Apr 30, 2025EPS Estimate
4.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.70
Shares Outstanding60,732,480
10 Day Avg. Volume1,584,831
30 Day Avg. Volume1,416,045
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)N/A
Price to Sales (P/S)2.07
Price to Cash Flow (P/CF)5.30
P/FCF Ratio5.30
Enterprise Value/Market Cap1.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.64
Enterprise Value/Ebitda8.62
Forecast
1Y Price Target
$186.82Price Target Upside80.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Jazz Pharmaceuticals News
PremiumCompany Announcements
Jazz Pharmaceuticals Completes Acquisition of Chimerix
PremiumStock Analysis & Ideas
TPB, ACB and JAZZ: Three Pot Stocks Flowering With Potential Upside
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceJazz's stock is considered undervalued with a price objective significantly higher than the current trading price, suggesting upside potential.
Manufacturing StrategyJazz Pharmaceuticals is expected to mitigate tariff impacts by working down inventory that is already in the US.
Product PipelineThe acquisition of Chimerix is expected to be highly accretive and bolster Jazz Pharmaceuticals' rare oncology portfolio.
Bears Say
Earnings ImpactAssuming tariffs start and last through the entirety of Trump's term, there is an estimated $(0.57) FY'25 EPS impact.
Investor SentimentInvestors are seen as cautious but the company's ability to accelerate US production could serve as a positive catalyst.
Tariffs ImpactJazz's stock has traded down ~12% since Trump mentioned potential pharma tariffs on Irish drug imports.
---
Ownership Overview
3.46% Insiders
29.23% Mutual Funds
0.98% Other Institutional Investors
40.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $95.49 and its highest was $148.06 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $6.24B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Apr 30, 2025 which is in 7 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Feb 25, 2025. The company reported $6.6 earnings per share for the quarter, beating the consensus estimate of $5.862 by $0.738.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 4.73.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 60,732,480 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $6.6 in its last earnings report, beating expectations of $5.862. Following the earnings report the stock price went up 3.222%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in JAZZ
---
Jazz Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$186.82 (80.71% Upside)
$186.82 (80.71% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 11.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.73%
12-Months-Change
Fundamentals
Return on Equity
14.31%
Trailing 12-Months
Asset Growth
5.43%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
---
JAZZ Company Deck
---
JAZZ Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record revenues, successful product launches, and strong sales growth for key products like Epidiolex. However, challenges such as the impact of pediatric protocol changes on Rylaze and potential revenue erosion from upcoming generic competition were noted. The company demonstrated financial strength by reducing debt and maintaining strategic flexibility.Read More>---
JAZZ Stock 12 Month Forecast
Average Price Target
$186.82
▲(80.71% Upside)
Technical Analysis
Halozyme
―
Madrigal Pharmaceuticals
―
BridgeBio Pharma
―
Legend Biotech
―
Roivant Sciences
―
Best Analysts Covering JAZZ
1 Year
1 Year Success Rate
14/26 ratings generated profit
1 Year Average Return
+0.70%
reiterated a buy rating 2 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +0.70% per trade.
---